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gene found that actually would retard the
development ofbreast tumors-and it seems
to do that," said Anne Bowcock, a breast
cancer researcher and associate professor of
pediatrics at the University of Texas
Southwestern Medical Center in Dallas. "I
think it's a significant step toward the treat-
ment of at least some breast cancers." Most
ofthe 184,000 new breast cancer cases diag-
nosed annually are not the inherited type.
But the new research suggests that the pro-
tein produced by normal BRCA1 genes may
be effective against the more common non-
inherited forms ofbreast cancer.
Researchers led by Jeffrey Holt of
Vanderbilt first implanted normal BRCA1
genes into human breast and ovarian cancer
cells and found that cell growth was inhibit-
ed in vitro. Next, the researchers stably trans-
ferred either normal or mutant BRCA1 genes
into breast cancer cells and injected the cells
into mice. Tumors developed in all 15 mice
given mutant BRCA1, but in none ofthe 20
mice given normal BRCAI. Finally, the
researchers injected viruses carrying the
BRCA1 gene into the abdomens of 10 mice
with established breast cancer tumors; half
the mice got normal BRCA1, the others got
mutated BRCA1. The mice with mutant
BRCA1 all died ofcancer within two weeks.
Those with normal BRCA1 survived 15 to
41 days, and their tumors either shrank or
disappeared.
All the experiments used a cell line
derived from noninherited breast cancer, sug-
gesting that the treatment might work
against the more common types of the dis-
ease. Against hereditary breast and ovarian
cancer, "presumably it would have an even
more dramatic effect-at least that's what we
hope," said RoyJensen, an assistant professor
ofpathologyand cell biology atVanderbilt.
Translating the results into treatments
for human cancers will take time. "It's going
to be a long time before this is taken to the
bedside," said Bowcock. "The problem is
actually getting BRCA1 into breast cells-it's
not going to be easy."
It's easier to get BRCA1 into ovarian
tumor cells, and Vanderbilt researchers
recently began clinical trials using BRCA1 on
about 20 ovarian cancer patients, a move
that concerns some of their colleagues.
While he finds the results ofthe mouse and
cell culture experiments "intriguing" and
"encouraging," Roger Wiseman, head ofthe
Comparative Carcinogenesis Group of the
NIEHS Laboratory of Molecular
Carcinogenesis (part ofthe team that identi-
fied BRCA1) feels the human gene therapy
trials are "premature, based on the data that
have been presented so far." Wiseman would
like to see more animal studies performed
before BRCAJ is used in patients.
A related study led by Jensen found evi-
dence that the BRCA1 protein may be
secreted and do its work outside the cell. If
this is true, it would be much easier to
design and deliver drugs that mimic the pro-
tein's effects. However, this finding is con-
troverted, and other research groups are con-
vinced that the BRCA1 protein works from
inside cells.
"What we need to do to confirm our
theory is purify recombinant BRCAJ and
put it onto cells and see if it actually has a
growth inhibitory action," said Jensen. If it
does, and if it works only on breast and
ovarian cancer cells and not other cells,
"then that's pretty good evidence that there
are specific receptors for this protein. Our
efforts then would be focusing on trying to
find those receptors."
Fueling the Gas Debate
New findings continue to fuel the debate
over the safety and effectiveness of gasoline
additives, such as methyl tertiary butyl ether
(MTBE) and ethanol, being used to reduce
air pollution. The Clean Air Act
Amendments of 1990 required that, begin-
ning in 1992, areas that fail to meet air qual-
ity standards must use oxygenated fuels. Not
only has the effectiveness of the oxygenates
in reducing carbon monoxide (CO) emis-
sions been questioned, the additives have
also been accused ofcausing health problems
including headaches, dizziness, nausea, and
rashes. However, a recent study has found
that the additives are successful in reducing
CO emissions and do not appear likely to
substantially increase health risks when com-
pared to normal gasoline. The report
Genetics and Biosafety
With the pounding pace at which research in genetics and biotechnology is progressing, it
has become increasingly difficult forscientists to stayabreast ofall the advances and ensure
that the new technology is being used in a safe and cautious manner. In an effort to
improve communications among scientists and promote the safe use ofbiotechnology, the
United Nations established the International Centre for Genetic Engineering and
Biotechnology (ICGEB).
The center maintains two main research laboratories, one in Trieste,
Italy, and another in New Delhi, India, with several other smaller labs scat-
tered around the world. These laboratories distribute their findings along
with other biology-related information over the Internet via the ICGEB
home page and ICGEBnet, an information resource network for molecular
biologists.
The ICGEB home page, located athttpdJ/bascicgeb.trieit/, provides
information on ICGEB-sponsored meetings and symposia, access to biology-
related databases and newsgroups, and information on accessing ICGEBnet. 3)
Asecond biology-related network available from the home page called BIN21 is still being
developed bytheICGEB andwill focus on issues ofbiodiversity.
Among the databases accessible from the ICGEB's home page is one relating to P450
proteins and P450-containing systems, an on-line directory ofbiologists around theworld,
and SBASE (a sequence database ofprotein domains). An extensive library of biosafety-
related rules andregulations fromvarious nations, organizations, and research institutions is
also available, along with lists of experts and databases that can be contacted to help
researchers in dealing with biology-related legal issues. For further assistance on biosafety
and legal questions, a link is provided to the Stockholm Environment Institute's
Biotechnology Advisory Board home page. This international board of scientists will
answer questions and give advice on any issue relating to ecology, biochemistry, genetics,
biotechnology, pathology, environmental law, oreconomics.
Access to ICGEBnet andBIN21 will be free ofcharge butgenerally limited to scientists
andpolicymakers with apertinent interest in biology. Currently, ICGEBnet gives scientists
around theworld access to avarietyofdatabases andprovides acomputer environment that
allows molecular biologists to analyze nudeotide and protein sequences. Analysis software,
induding three major program packages, is distributed over ICGEBnet. In addition, infor-
mation services such as electronic mail and bulletin boards are also available. The center's
goal is to distribute these services to areas ofthe developing world where they are not yet
widelyavailable.
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